Skip to content
OpenCapital
Get started

Avalo Therapeutics AVTX AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss at other companies

Exelixis logo
ExelixisEXEL
——

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$20.9M-42.5%
Net income-$19.6M-49.3%
EPS (diluted)-$0.98+21.6%

Balance sheet

See full
Cash & equivalents$25.3M-79.8%
Total debt$328.0K-59.1%
Total equity$68.3M-44.3%
Total assets$99.9M-27.9%

Cash flow

See full
Operating cash flow-$17.7M-87.1%
CapEx-—
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$946.18M+1,783%
Enterprise value$921.19M-1,342%
P/S1,892.4×+1,852×

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-88.8%—
Debt / equity0×0.0×
Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's afs and trading securities - unrealized loss position (>=12 months) accumulated loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avalo Therapeutics's AFS and trading securities - unrealized loss position (>=12 months) accumulated loss?
Avalo Therapeutics (AVTX) reported AFS and trading securities - unrealized loss position (>=12 months) accumulated loss of $0 in Q1 2026.